- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02887053
Methodological Developments for Magnetic Resonance Imaging (MRI) (METHODO)
July 19, 2022 updated by: Valérie LAURENT, Central Hospital, Nancy, France
Développement Méthodologique de l'Imagerie Par Résonance Magnétique (IRM)
The purpose of this study is to optimize clinical MR protocols and to validate MR acquisition parameters.
Study Overview
Study Type
Interventional
Enrollment (Actual)
1807
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nancy, France, 5400
- CHRU de Nancy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- to be over 18 year-old,
- to be able to give an informed consent,
- to have underwent a pre-inclusion medical examination,
- to present no contraindication to MR examination,
- to be enrolled in a social security plan.
Exclusion Criteria:
- subject refusal,
- subject under a measure of legal protection,
- any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All subjects
All subjects will have an MRI examination
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Image quality based on standard imaging quality criteria
Time Frame: 6 months after the last inclusion
|
Image quality criteria will be :
|
6 months after the last inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
T1/T2 Quantitative sub studies
Time Frame: 6 months after the last inclusion
|
For quantitative studies such as T1/T2 studies a T1/T2 quantification will be calculated.
These parameters will be reported in ms.
|
6 months after the last inclusion
|
Brain Functional MRI sub studies
Time Frame: 6 months after the last inclusion
|
For functional MRI studies, brain activity will be described in terms of brain localisation based on blood oxygen level-dependent signal variation and its intensity.
|
6 months after the last inclusion
|
Cardiac function MRI sub studies: volume
Time Frame: 6 months after the last inclusion
|
For cardiac imaging, cardiac function will be evaluated.
Parameters such as left ventricle (LV) and right ventricle (RV) end-diastolic volumes end-systolic volumes will be measured and reported in mL/m².
|
6 months after the last inclusion
|
Cardiac mass MRI sub studies: mass
Time Frame: 6 months after the last inclusion
|
For cardiac imaging, cardiac function will be evaluated.
LV and RV mass index will be measured and reported in g/m2.
|
6 months after the last inclusion
|
Cardiac function MRI sub studies: ejection fraction
Time Frame: 6 months after the last inclusion
|
For cardiac imaging, cardiac function will be evaluated.
Ejection fraction for both ventricles will be calculated and reported in %.
|
6 months after the last inclusion
|
Diffusion weighted MRI sub studies
Time Frame: 6 months after the last inclusion
|
For diffusion studies, the apparent diffusion coefficient (ADC) whic is a measure of the magnitude of diffusion (of water molecules) within tissue will be estimated (mm2/s).
|
6 months after the last inclusion
|
Diffusion tensor MRI sub studies
Time Frame: 6 months after the last inclusion
|
The fractional anisotropy (FA) which is a scalar value between zero and one, which describes the degree of anisotropy of a diffusion process, could also be estimated.
|
6 months after the last inclusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Valérie Laurent, MD,PhD, CHRU de Nancy
- Principal Investigator: Jacques Felblinger, MD,PhD, CHRU de Nancy
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2008
Primary Completion (Actual)
May 26, 2022
Study Completion (Actual)
May 26, 2022
Study Registration Dates
First Submitted
July 15, 2016
First Submitted That Met QC Criteria
August 31, 2016
First Posted (Estimate)
September 1, 2016
Study Record Updates
Last Update Posted (Actual)
July 20, 2022
Last Update Submitted That Met QC Criteria
July 19, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2008-A01209-46
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsRecruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on MRI
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingMultiple SclerosisFrance
-
Cambridge University Hospitals NHS Foundation TrustRecruitingBreast CancerUnited Kingdom
-
Seoul National University Bundang HospitalBayerCompletedTraumaKorea, Republic of
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedOsteosarcoma | Ewing Sarcoma | Paget's DiseaseUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
University of ZurichBalgrist University HospitalNot yet recruiting
-
Bragee ClinicsNot yet recruitingChronic Fatigue Syndrome
-
Brighton and Sussex University Hospitals NHS TrustCompletedLacrimal Duct Obstruction | Lacrimal StenosisUnited Kingdom
-
Rennes University HospitalBayerTerminatedMultiple Sclerosis (MS) | Inflammatory DiseaseFrance
-
Memorial Sloan Kettering Cancer CenterTerminated